Author of the article:
Published May 29, 2024 • 2 minute read
VANCOUVER, British Columbia — Kardium Inc., a private medical device company that has developed the Globe® System for the treatment of atrial fibrillation (AF), announced positive results of the 1-year outcomes of the First-in-Human PULSE-EU Trial. These findings were presented as late-breaking clinical data at the Heart Rhythm Society (HRS) 2024 Annual Meeting and simultaneously published in the Heart Rhythm Journal.
“I am very excited by the results of the PULSE-EU Study with the Globe Pulsed Field System” said Dr. Vivek Reddy of The Mount Sinai Hospital, New York, who presented the data at HRS. “The Globe System achieved outstanding freedom from atrial arrhythmia in both Paroxysmal and Persistent patients, with no device- or procedure-related major adverse events. These outcomes underscore the tremendous potential of the Globe System in advancing AF treatment and improving patient outcomes.”
Advertisement 2
This advertisement has not loaded yet, but your article continues below.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
Exclusive articles from Barbara Shecter, Joe O’Connor, Gabriel Friedman, Victoria Wells and others.Daily content from Financial Times, the world’s leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
Exclusive articles from Barbara Shecter, Joe O’Connor, Gabriel Friedman, Victoria Wells and others.Daily content from Financial Times, the world’s leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.
Sign In or Create an Account
or
Article content
Article content
The results demonstrated in the PULSE-EU study in patients receiving the optimized Pulsed Field (PF) dose included:
Durable Clinical Effectiveness:
Acute isolation was achieved in 100% of pulmonary veins (PVs).Freedom from atrial arrhythmia at 1 year was 84.2% in paroxysmal AF patients and 80% in persistent AF patients.
Enhanced Procedural Safety:
Zero device or procedure-related major adverse events (defined as death, phrenic nerve palsy, pericardial tamponade, pulmonary vein stenosis or esophageal complications)
Efficient Procedural Workflow:
Average time to isolate all pulmonary veins was 23 minutes.True single-shot isolation with an average of just 1.2 PF applications per pulmonary vein.Low average fluoroscopy time of only 5 minutes.
“These excellent results of the PULSE-EU Trial reflect Kardium’s ongoing dedication to develop the best treatment for Atrial Fibrillation”, said Kevin Chaplin, CEO of Kardium. “These findings highlight the potential of the Globe System to set new standards in the treatment of atrial fibrillation, with the potential to offer a safe and more effective therapeutic option for patients. Everyone at Kardium looks forward to further advancing our Globe technology and making it available to patients worldwide.”
About Kardium
Kardium Inc. ( kardium.com) is a rapidly growing, privately held medical solutions company that has developed an advanced system for atrial fibrillation (AF) treatment: the Globe System. Kardium has built an outstanding team, who have worked with top medical advisors to develop the Globe System. Founded in 2007 and headquartered in Vancouver, Canada, Kardium has consistently ranked as one of the top companies to work for in British Columbia.
This press release may contain forward-looking statements, which reflect current expectations regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, performance or achievements to be materially different from those expressed or implied by such statements. The Globe System is restricted by federal law to investigational use only, and it has not been approved or cleared for commercial distribution in any jurisdictions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529708222/en/
Contacts
Stefan Avall
VP, Product Management
Kardium Inc.
stefan.avall@kardium.com
604-248-8891 x285
Article content
>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Financial Post – https://financialpost.com/pmn/business-wire-news-releases-pmn/kardium-announces-positive-1-year-outcomes-for-pulse-eu-trial-with-the-globe-system-showing-promise-for-improving-the-treatment-of-atrial-fibrillation